Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Global medical device manufacturer procures Sono-Tek's MediCoat stent coating systems worth $400,000

Sono-Tek Corporation (OTC Bulletin Board: SOTK) announced today the sale of a series of its MediCoat DES 2000 stent coating systems to a leading global medical device manufacturer. The sale is Sono-Tek's largest ever sales transaction to the medical device industry, valued at approximately $400,000.

16 Sep 2009

SSO2 administration reduces heart muscle damage

Supersaturated oxygen (SSO2) administered during catheter-based treatments for heart attack can significantly reduce heart muscle damage, according to a new study reported in Circulation: Cardiovascular Interventions, a journal of the American Heart Association.

16 Sep 2009

Study shows 29 percent patients experienced angina chest pain once a week

The world's largest quality of life study of chronic angina patients has revealed that almost one in three experience frequent chest pain, which affects their daily life.

16 Sep 2009

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that the company’s Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at a bifurcation in patients with heart disease.

15 Sep 2009

Clinical trial data of Genous Bio-engineered R stent to be presented

Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

15 Sep 2009

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

14 Sep 2009

Study reveals feasibility of OrbusNeich's Genous stent in patients needing undeferrable non-cardiac surgery

OrbusNeich's Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy, according to a paper published online in the International Journal of Cardiology (Int J Cardiol. 2009 Aug 21. [Epub ahead of print]).

14 Sep 2009

U.S patent for Tryton Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that a U.S. patent has been awarded for the company’s Tryton Side Branch Stent™ System.

10 Sep 2009

Free, online self-assessment quiz helps assess health and lifestyle risks for PAD

As recent medical studies continue to highlight the seriousness of peripheral arterial disease (or PAD) and its association with heart attack, stroke and early mortality, the Society of Interventional Radiology Foundation recommends that older Americans, smokers and diabetics take its free, online self-assessment quiz.

10 Sep 2009

Society of Interventional Radiology's resources emphasize on PAD

The Society of Interventional Radiology offers numerous resources just in time for September's national peripheral arterial disease (or PAD) awareness month. As recent medical studies continue to highlight the seriousness of PAD, these resources are welcome additions to libraries for interventional radiologists and primary care physicians who want to learn more about minimally invasive treatments for this disease that affects an estimated 10 million people in the United States.

10 Sep 2009

Many high health costs remain mysterious, including the cost of reform

Health care's high costs are a main reason lawmakers are taking on health reform, but it's also a challenge to identify and target the many reasons care is so expensive. NPR takes a look at medical devices, like plastic tubes and scalpels, that boast surprisingly big price tags. A $2,000 dollar metal stent must be tiny and flexible, a $60 plastic catheter must bend in exactly the right way and "the market is still sorting itself out" on the appropriate price of relatively new specialty scalpels used for heart surgery (Joffe-Walt 9/4).

5 Sep 2009

Boston Scientific reports two-year data from SYNTAX clinical trial

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.

3 Sep 2009

SYNTAX clinical trial results announced

Boston Scientific Corporation (NYSE: BSX) today announced two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the TAXUS((R)) Express((R)) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.

3 Sep 2009

Primary angioplasty procedures vary in European countries

Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.

2 Sep 2009

PLATO study reveals that ticagrelor reduces the rate of cardiovascular events

The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta) reduced the rate of cardiovascular (CV) events (CV death, myocardial infarction or stroke) from 11.7% to 9.8% compared clopidogrel (Plavix®) XX% (p<0.001, RRR = 16%), without an increase in major bleeding.

2 Sep 2009

Immediate catheterization not always better for ACS patients

For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.

1 Sep 2009

Reperfusion therapy proves beneficial for patients with heart attacks

The wider use of reperfusion therapy in patients with heart attack (AMI) can save millions of lives in Europe. Effective reperfusion therapy in an AMI patient can cut the individual risk of dying by half.

1 Sep 2009

Cordis enrolls first patient in the CYPRESS clinical study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.

31 Aug 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

31 Aug 2009

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009